Disposable Fully Automatic Biopsy Device Market by Type (Core Needle, Fine Needle Aspiration, Vacuum Assisted), Guidance Type (CT, MRI, Stereotactic), Application, End User - Global Forecast 2026-2032
Description
The Disposable Fully Automatic Biopsy Device Market was valued at USD 302.21 million in 2025 and is projected to grow to USD 330.08 million in 2026, with a CAGR of 6.37%, reaching USD 465.93 million by 2032.
A concise orienting overview that synthesizes clinical demand drivers, engineering advances, and procurement dynamics shaping disposable fully automatic biopsy devices
The disposable fully automatic biopsy device sector sits at the intersection of clinical need, engineering innovation, and evolving healthcare delivery models. New device architectures, coupled with advances in imaging guidance and automation, are reshaping how tissue sampling is performed across outpatient and inpatient settings. Clinicians are increasingly focused on devices that reduce procedure time, minimize patient discomfort, and deliver consistent sampling quality to support precision diagnostics and downstream molecular testing.
Against this backdrop, stakeholders must reconcile clinical performance expectations with practical considerations such as device ergonomics, single-use safety benefits, and supply chain resilience. Innovations in motorized actuation and integrated vacuum systems aim to standardize sampling mechanics, while compatibility with multiple guidance modalities expands clinical applicability. As reimbursement paradigms and hospital procurement practices shift toward value-based care, the ability of device manufacturers to demonstrate reproducible diagnostic yield, ease of use, and infection control advantages will determine adoption trajectories.
An analytical narrative describing how clinical expectations, automation technologies, and care delivery trends are reshaping device innovation and adoption patterns
The landscape for disposable fully automatic biopsy devices is undergoing transformative shifts driven by converging clinical, technological, and operational forces. Clinically, the move toward minimally invasive diagnostics and the increasing reliance on molecular pathology have raised expectations for sample integrity and repeatable performance, prompting developers to prioritize mechanisms that preserve tissue architecture and reduce crush artifact. Technologically, enhancements in automation, sensor integration, and motorized vacuum systems are enabling devices that deliver consistent core samples while reducing the manual dexterity required from operators.
Operationally, changes in care delivery are accelerating adoption of devices suited to ambulatory surgical centers and outpatient clinics, where throughput, sterility, and simplified reprocessing are paramount. Concurrently, imaging guidance modalities are becoming more diverse and accessible, with ultrasound and advanced CT workflows enabling point-of-care procedures that lower procedural overhead. Taken together, these shifts create a competitive environment where cross-disciplinary expertise-combining clinical insight, hardware engineering, and supply chain management-delivers differentiated value to health systems and clinicians.
A focused examination of how 2025 United States tariff measures are reshaping sourcing, pricing, and procurement behaviors across the biopsy device value chain
The implementation of new tariff policies in the United States in 2025 has introduced layered effects across the disposable fully automatic biopsy device value chain, altering cost structures, supplier strategies, and procurement behaviors. Import-dependent components such as precision motors, sterile disposable plastics, and imaging-compatible consumables have experienced input cost pressure, prompting manufacturers to reassess sourcing strategies and materials engineering. In turn, procurement teams at hospitals and ambulatory centers have intensified price sensitivity, favoring suppliers able to absorb cost shocks or demonstrate local manufacturing resiliency.
Consequently, firms with diversified supplier bases and nearshoring capabilities have seen a relative strategic advantage, enabling more predictable lead times and reduced exposure to cross-border tariff volatility. The tariff environment has also accelerated conversations about product rationalization, whereby companies prioritize core models that deliver the broadest clinical utility with streamlined bill-of-materials complexity. At the regulatory and policy level, stakeholders are monitoring whether tariff-driven cost increases translate into reimbursement tensions or altered adoption curves in budget-constrained settings. Looking forward, sustained dialogue between manufacturers and purchasers will determine whether short-term cost impacts evolve into long-term structural shifts in sourcing and pricing practices.
A granular segmentation synthesis that links device architectures, clinical applications, imaging guidance modalities, and care settings to adoption imperatives and product differentiation
Segmentation analysis reveals differentiated technology choices and clinical use patterns that should guide product development and market entry strategies. Based on type, the market divides into core needle, fine needle aspiration, and vacuum assisted devices, where core needle platforms further bifurcate into automated core variants and manual core designs, fine needle aspiration splits into multiple needle and single needle configurations, and vacuum assisted systems include manual vacuum and motorized vacuum solutions; these distinctions matter because each subtype aligns with specific procedural objectives, tissue requirements, and user preferences. Based on application, devices serve breast, liver, lung, and prostate procedures, with breast use further distinguished by diagnostic and screening contexts, while liver, lung, and prostate applications each encompass diagnostic and therapeutic roles; understanding these application-level differences helps clarify performance priorities such as sample volume, lesion targeting fidelity, and bleeding risk mitigation.
Based on guidance type, clinical workflows involve CT, MRI, stereotactic, and ultrasound guidance modalities, with CT applications extending into cone beam and helical CT variants, MRI usage spanning closed and open systems, stereotactic procedures employing frame based and frameless approaches, and ultrasound guidance available in 2D, 3D, and Doppler forms; compatibility across these imaging approaches influences device ergonomics and couplings. Based on end user, the adoption environment spans ambulatory surgical centers, clinics, diagnostic laboratories, and hospitals, wherein ambulatory centers separate into freestanding and hospital based centers, clinics break into general practice and specialty clinics, diagnostic laboratories distinguish hospital based and independent labs, and hospitals are categorized as private or public institutions; each end user type presents unique procurement cycles, clinical staffing models, and infection control expectations that shape purchasing decisions.
Comparative regional intelligence that explains how unique healthcare systems, procurement behaviors, and infrastructure investments drive differentiated demand for biopsy devices
Regional dynamics create distinct demand drivers and operational considerations that inform market strategies. In the Americas, health systems increasingly focus on outpatient expansion, accelerated adoption of minimally invasive procedures, and integrated diagnostic pathways that emphasize time-to-diagnosis and procedural efficiency; reimbursement frameworks and large private provider networks influence purchasing cadence, while an emphasis on infection control supports single-use device adoption. In Europe, the Middle East & Africa, regulatory diversity and heterogeneous procurement models create a patchwork of adoption patterns where centralized tenders coexist with private hospital procurement; reimbursement mechanisms and national health priorities shape uptake, and regional innovation hubs drive targeted clinical collaborations. In Asia-Pacific, expanding diagnostic services, investments in advanced imaging infrastructure, and growing demand for point-of-care solutions create fertile ground for products that combine affordability with robust clinical performance.
Across these regions, supply chain resilience, local regulatory navigation, and partnerships with regional clinical champions determine success. Manufacturers should calibrate market entry and commercialization tactics to reflect regional training requirements, device registration timelines, and the relative importance of price versus clinical differentiation. Furthermore, transitional dynamics such as shifts in outpatient care models and imaging accessibility are converging globally, creating opportunities for platforms that can scale across multiple regional contexts with localized support and training programs.
An integrated view of competitive differentiators showing how technology choices, clinical evidence strategies, and supply chain approaches establish market leadership
Competitive landscapes are shaped by a combination of engineering excellence, regulatory execution, and commercial reach. Leading companies have invested in modular platforms that support both automated core sampling and vacuum assisted techniques, while also ensuring cross-compatibility with multiple imaging guidance systems. Strategic partnerships with imaging vendors, pathology laboratories, and key clinical opinion leaders have accelerated clinical validation programs and strengthened adoption trajectories. In parallel, newer entrants often focus on niche differentiation, such as motorized vacuum performance, single-use sterility guarantees, or streamlined disposable packaging to reduce waste and improve workflow.
Beyond product design, successful players have deployed comprehensive training programs and clinical support services that reduce procedural variability and build clinician confidence. Supply chain vertical integration and nearshoring strategies have emerged as competitive levers to mitigate tariff-related volatility and preserve margin. Finally, companies that prioritize evidence generation-through peer-reviewed clinical studies and real-world performance datasets-have been more effective at securing hospital formulary inclusion and payer recognition, creating a virtuous cycle between evidence, adoption, and incremental product refinement.
Practical and prioritized actions that align product design, clinical evidence, supply chain resilience, and market engagement to accelerate adoption and reduce commercial risk
Industry leaders should pursue a coordinated set of tactical and strategic moves to secure market position and accelerate adoption. First, prioritize engineering efforts that harmonize automated core sampling and motorized vacuum capabilities while maintaining manufacturability and sterile single-use benefits; product roadmaps should emphasize modularity to support multiple guidance modalities and to simplify inventory management. Second, invest in robust clinical evidence generation focused on comparative performance, procedural efficiency, and patient-centric outcomes; real-world data initiatives and multicenter studies will increase credibility with hospital procurement committees and payers.
Third, strengthen supply chain resilience through supplier diversification and regional manufacturing partnerships to reduce exposure to tariff-induced cost fluctuation and to improve lead times. Fourth, establish targeted commercialization programs that address the specific purchasing behaviors of ambulatory surgical centers, specialty clinics, and hospital systems, complementing product launches with clinician education, hands-on training, and technical support services. Fifth, engage proactively with regulatory and reimbursement stakeholders to clarify value propositions and to reduce friction in market entry. By aligning product innovation with evidence, supply chain agility, and targeted market engagement, companies can create defensible differentiation and accelerate clinician adoption across care settings.
A transparent mixed-methods research framework combining primary clinical interviews, technical and regulatory review, and supply chain mapping for robust market insights
This research combines a mixed-methods approach that integrates primary interviews with clinical stakeholders, secondary literature review of peer-reviewed clinical studies and regulatory filings, and qualitative analysis of procurement and manufacturing practices. Primary inputs include structured discussions with interventional radiologists, breast and thoracic surgeons, pathology leaders, and procurement professionals to capture procedural needs, usability considerations, and purchasing drivers. Secondary sources encompass device technical specifications, regulatory clearances, clinical trial registries, and guideline statements that inform comparative performance and safety profiles.
The analytic framework triangulates clinical insights with engineering assessments and supply chain mapping to identify strategic vulnerabilities and opportunities. Data validation steps include cross-referencing interview findings with published clinical outcomes and device labeling, while sensitivity checks assess how changes in input costs or guidance modality adoption could alter stakeholder priorities. Throughout, the methodology maintains a focus on actionable intelligence, emphasizing operationally relevant variables such as device compatibility with imaging systems, single-use benefits for infection control, and manufacturability considerations that affect cost and scalability.
A concluding synthesis that ties clinical imperatives, operational realities, and strategic levers into a clear pathway for sustained adoption and commercial success
The disposable fully automatic biopsy device arena is at an inflection point where technology maturation, evolving care delivery models, and policy shifts converge to reshape adoption pathways. Devices that deliver consistent, high-quality tissue samples while simplifying workflows and supporting infection control are best positioned to meet clinician and institutional needs. At the same time, geopolitical and tariff dynamics have highlighted the importance of supply chain strategy and cost containment as decisive factors in procurement decisions.
Therefore, success will favor organizations that integrate strong clinical evidence programs with modular, imaging-agnostic product designs and resilient manufacturing footprints. Strategic engagement with end users and regional stakeholders will accelerate translation from product capability to routine clinical practice. Ultimately, the companies that combine technical performance, economic pragmatism, and operational support will define the next generation of standard-of-care tissue sampling solutions.
Note: PDF & Excel + Online Access - 1 Year
A concise orienting overview that synthesizes clinical demand drivers, engineering advances, and procurement dynamics shaping disposable fully automatic biopsy devices
The disposable fully automatic biopsy device sector sits at the intersection of clinical need, engineering innovation, and evolving healthcare delivery models. New device architectures, coupled with advances in imaging guidance and automation, are reshaping how tissue sampling is performed across outpatient and inpatient settings. Clinicians are increasingly focused on devices that reduce procedure time, minimize patient discomfort, and deliver consistent sampling quality to support precision diagnostics and downstream molecular testing.
Against this backdrop, stakeholders must reconcile clinical performance expectations with practical considerations such as device ergonomics, single-use safety benefits, and supply chain resilience. Innovations in motorized actuation and integrated vacuum systems aim to standardize sampling mechanics, while compatibility with multiple guidance modalities expands clinical applicability. As reimbursement paradigms and hospital procurement practices shift toward value-based care, the ability of device manufacturers to demonstrate reproducible diagnostic yield, ease of use, and infection control advantages will determine adoption trajectories.
An analytical narrative describing how clinical expectations, automation technologies, and care delivery trends are reshaping device innovation and adoption patterns
The landscape for disposable fully automatic biopsy devices is undergoing transformative shifts driven by converging clinical, technological, and operational forces. Clinically, the move toward minimally invasive diagnostics and the increasing reliance on molecular pathology have raised expectations for sample integrity and repeatable performance, prompting developers to prioritize mechanisms that preserve tissue architecture and reduce crush artifact. Technologically, enhancements in automation, sensor integration, and motorized vacuum systems are enabling devices that deliver consistent core samples while reducing the manual dexterity required from operators.
Operationally, changes in care delivery are accelerating adoption of devices suited to ambulatory surgical centers and outpatient clinics, where throughput, sterility, and simplified reprocessing are paramount. Concurrently, imaging guidance modalities are becoming more diverse and accessible, with ultrasound and advanced CT workflows enabling point-of-care procedures that lower procedural overhead. Taken together, these shifts create a competitive environment where cross-disciplinary expertise-combining clinical insight, hardware engineering, and supply chain management-delivers differentiated value to health systems and clinicians.
A focused examination of how 2025 United States tariff measures are reshaping sourcing, pricing, and procurement behaviors across the biopsy device value chain
The implementation of new tariff policies in the United States in 2025 has introduced layered effects across the disposable fully automatic biopsy device value chain, altering cost structures, supplier strategies, and procurement behaviors. Import-dependent components such as precision motors, sterile disposable plastics, and imaging-compatible consumables have experienced input cost pressure, prompting manufacturers to reassess sourcing strategies and materials engineering. In turn, procurement teams at hospitals and ambulatory centers have intensified price sensitivity, favoring suppliers able to absorb cost shocks or demonstrate local manufacturing resiliency.
Consequently, firms with diversified supplier bases and nearshoring capabilities have seen a relative strategic advantage, enabling more predictable lead times and reduced exposure to cross-border tariff volatility. The tariff environment has also accelerated conversations about product rationalization, whereby companies prioritize core models that deliver the broadest clinical utility with streamlined bill-of-materials complexity. At the regulatory and policy level, stakeholders are monitoring whether tariff-driven cost increases translate into reimbursement tensions or altered adoption curves in budget-constrained settings. Looking forward, sustained dialogue between manufacturers and purchasers will determine whether short-term cost impacts evolve into long-term structural shifts in sourcing and pricing practices.
A granular segmentation synthesis that links device architectures, clinical applications, imaging guidance modalities, and care settings to adoption imperatives and product differentiation
Segmentation analysis reveals differentiated technology choices and clinical use patterns that should guide product development and market entry strategies. Based on type, the market divides into core needle, fine needle aspiration, and vacuum assisted devices, where core needle platforms further bifurcate into automated core variants and manual core designs, fine needle aspiration splits into multiple needle and single needle configurations, and vacuum assisted systems include manual vacuum and motorized vacuum solutions; these distinctions matter because each subtype aligns with specific procedural objectives, tissue requirements, and user preferences. Based on application, devices serve breast, liver, lung, and prostate procedures, with breast use further distinguished by diagnostic and screening contexts, while liver, lung, and prostate applications each encompass diagnostic and therapeutic roles; understanding these application-level differences helps clarify performance priorities such as sample volume, lesion targeting fidelity, and bleeding risk mitigation.
Based on guidance type, clinical workflows involve CT, MRI, stereotactic, and ultrasound guidance modalities, with CT applications extending into cone beam and helical CT variants, MRI usage spanning closed and open systems, stereotactic procedures employing frame based and frameless approaches, and ultrasound guidance available in 2D, 3D, and Doppler forms; compatibility across these imaging approaches influences device ergonomics and couplings. Based on end user, the adoption environment spans ambulatory surgical centers, clinics, diagnostic laboratories, and hospitals, wherein ambulatory centers separate into freestanding and hospital based centers, clinics break into general practice and specialty clinics, diagnostic laboratories distinguish hospital based and independent labs, and hospitals are categorized as private or public institutions; each end user type presents unique procurement cycles, clinical staffing models, and infection control expectations that shape purchasing decisions.
Comparative regional intelligence that explains how unique healthcare systems, procurement behaviors, and infrastructure investments drive differentiated demand for biopsy devices
Regional dynamics create distinct demand drivers and operational considerations that inform market strategies. In the Americas, health systems increasingly focus on outpatient expansion, accelerated adoption of minimally invasive procedures, and integrated diagnostic pathways that emphasize time-to-diagnosis and procedural efficiency; reimbursement frameworks and large private provider networks influence purchasing cadence, while an emphasis on infection control supports single-use device adoption. In Europe, the Middle East & Africa, regulatory diversity and heterogeneous procurement models create a patchwork of adoption patterns where centralized tenders coexist with private hospital procurement; reimbursement mechanisms and national health priorities shape uptake, and regional innovation hubs drive targeted clinical collaborations. In Asia-Pacific, expanding diagnostic services, investments in advanced imaging infrastructure, and growing demand for point-of-care solutions create fertile ground for products that combine affordability with robust clinical performance.
Across these regions, supply chain resilience, local regulatory navigation, and partnerships with regional clinical champions determine success. Manufacturers should calibrate market entry and commercialization tactics to reflect regional training requirements, device registration timelines, and the relative importance of price versus clinical differentiation. Furthermore, transitional dynamics such as shifts in outpatient care models and imaging accessibility are converging globally, creating opportunities for platforms that can scale across multiple regional contexts with localized support and training programs.
An integrated view of competitive differentiators showing how technology choices, clinical evidence strategies, and supply chain approaches establish market leadership
Competitive landscapes are shaped by a combination of engineering excellence, regulatory execution, and commercial reach. Leading companies have invested in modular platforms that support both automated core sampling and vacuum assisted techniques, while also ensuring cross-compatibility with multiple imaging guidance systems. Strategic partnerships with imaging vendors, pathology laboratories, and key clinical opinion leaders have accelerated clinical validation programs and strengthened adoption trajectories. In parallel, newer entrants often focus on niche differentiation, such as motorized vacuum performance, single-use sterility guarantees, or streamlined disposable packaging to reduce waste and improve workflow.
Beyond product design, successful players have deployed comprehensive training programs and clinical support services that reduce procedural variability and build clinician confidence. Supply chain vertical integration and nearshoring strategies have emerged as competitive levers to mitigate tariff-related volatility and preserve margin. Finally, companies that prioritize evidence generation-through peer-reviewed clinical studies and real-world performance datasets-have been more effective at securing hospital formulary inclusion and payer recognition, creating a virtuous cycle between evidence, adoption, and incremental product refinement.
Practical and prioritized actions that align product design, clinical evidence, supply chain resilience, and market engagement to accelerate adoption and reduce commercial risk
Industry leaders should pursue a coordinated set of tactical and strategic moves to secure market position and accelerate adoption. First, prioritize engineering efforts that harmonize automated core sampling and motorized vacuum capabilities while maintaining manufacturability and sterile single-use benefits; product roadmaps should emphasize modularity to support multiple guidance modalities and to simplify inventory management. Second, invest in robust clinical evidence generation focused on comparative performance, procedural efficiency, and patient-centric outcomes; real-world data initiatives and multicenter studies will increase credibility with hospital procurement committees and payers.
Third, strengthen supply chain resilience through supplier diversification and regional manufacturing partnerships to reduce exposure to tariff-induced cost fluctuation and to improve lead times. Fourth, establish targeted commercialization programs that address the specific purchasing behaviors of ambulatory surgical centers, specialty clinics, and hospital systems, complementing product launches with clinician education, hands-on training, and technical support services. Fifth, engage proactively with regulatory and reimbursement stakeholders to clarify value propositions and to reduce friction in market entry. By aligning product innovation with evidence, supply chain agility, and targeted market engagement, companies can create defensible differentiation and accelerate clinician adoption across care settings.
A transparent mixed-methods research framework combining primary clinical interviews, technical and regulatory review, and supply chain mapping for robust market insights
This research combines a mixed-methods approach that integrates primary interviews with clinical stakeholders, secondary literature review of peer-reviewed clinical studies and regulatory filings, and qualitative analysis of procurement and manufacturing practices. Primary inputs include structured discussions with interventional radiologists, breast and thoracic surgeons, pathology leaders, and procurement professionals to capture procedural needs, usability considerations, and purchasing drivers. Secondary sources encompass device technical specifications, regulatory clearances, clinical trial registries, and guideline statements that inform comparative performance and safety profiles.
The analytic framework triangulates clinical insights with engineering assessments and supply chain mapping to identify strategic vulnerabilities and opportunities. Data validation steps include cross-referencing interview findings with published clinical outcomes and device labeling, while sensitivity checks assess how changes in input costs or guidance modality adoption could alter stakeholder priorities. Throughout, the methodology maintains a focus on actionable intelligence, emphasizing operationally relevant variables such as device compatibility with imaging systems, single-use benefits for infection control, and manufacturability considerations that affect cost and scalability.
A concluding synthesis that ties clinical imperatives, operational realities, and strategic levers into a clear pathway for sustained adoption and commercial success
The disposable fully automatic biopsy device arena is at an inflection point where technology maturation, evolving care delivery models, and policy shifts converge to reshape adoption pathways. Devices that deliver consistent, high-quality tissue samples while simplifying workflows and supporting infection control are best positioned to meet clinician and institutional needs. At the same time, geopolitical and tariff dynamics have highlighted the importance of supply chain strategy and cost containment as decisive factors in procurement decisions.
Therefore, success will favor organizations that integrate strong clinical evidence programs with modular, imaging-agnostic product designs and resilient manufacturing footprints. Strategic engagement with end users and regional stakeholders will accelerate translation from product capability to routine clinical practice. Ultimately, the companies that combine technical performance, economic pragmatism, and operational support will define the next generation of standard-of-care tissue sampling solutions.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
190 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Definition
- 1.3. Market Segmentation & Coverage
- 1.4. Years Considered for the Study
- 1.5. Currency Considered for the Study
- 1.6. Language Considered for the Study
- 1.7. Key Stakeholders
- 2. Research Methodology
- 2.1. Introduction
- 2.2. Research Design
- 2.2.1. Primary Research
- 2.2.2. Secondary Research
- 2.3. Research Framework
- 2.3.1. Qualitative Analysis
- 2.3.2. Quantitative Analysis
- 2.4. Market Size Estimation
- 2.4.1. Top-Down Approach
- 2.4.2. Bottom-Up Approach
- 2.5. Data Triangulation
- 2.6. Research Outcomes
- 2.7. Research Assumptions
- 2.8. Research Limitations
- 3. Executive Summary
- 3.1. Introduction
- 3.2. CXO Perspective
- 3.3. Market Size & Growth Trends
- 3.4. Market Share Analysis, 2025
- 3.5. FPNV Positioning Matrix, 2025
- 3.6. New Revenue Opportunities
- 3.7. Next-Generation Business Models
- 3.8. Industry Roadmap
- 4. Market Overview
- 4.1. Introduction
- 4.2. Industry Ecosystem & Value Chain Analysis
- 4.2.1. Supply-Side Analysis
- 4.2.2. Demand-Side Analysis
- 4.2.3. Stakeholder Analysis
- 4.3. Porter’s Five Forces Analysis
- 4.4. PESTLE Analysis
- 4.5. Market Outlook
- 4.5.1. Near-Term Market Outlook (0–2 Years)
- 4.5.2. Medium-Term Market Outlook (3–5 Years)
- 4.5.3. Long-Term Market Outlook (5–10 Years)
- 4.6. Go-to-Market Strategy
- 5. Market Insights
- 5.1. Consumer Insights & End-User Perspective
- 5.2. Consumer Experience Benchmarking
- 5.3. Opportunity Mapping
- 5.4. Distribution Channel Analysis
- 5.5. Pricing Trend Analysis
- 5.6. Regulatory Compliance & Standards Framework
- 5.7. ESG & Sustainability Analysis
- 5.8. Disruption & Risk Scenarios
- 5.9. Return on Investment & Cost-Benefit Analysis
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Disposable Fully Automatic Biopsy Device Market, by Type
- 8.1. Core Needle
- 8.1.1. Automated Core
- 8.1.2. Manual Core
- 8.2. Fine Needle Aspiration
- 8.2.1. Multiple Needle
- 8.2.2. Single Needle
- 8.3. Vacuum Assisted
- 8.3.1. Manual Vacuum
- 8.3.2. Motorized Vacuum
- 9. Disposable Fully Automatic Biopsy Device Market, by Guidance Type
- 9.1. CT
- 9.1.1. Cone Beam CT
- 9.1.2. Helical CT
- 9.2. MRI
- 9.2.1. Closed MRI
- 9.2.2. Open MRI
- 9.3. Stereotactic
- 9.3.1. Frame Based
- 9.3.2. Frameless
- 9.4. Ultrasound
- 9.4.1. 2D Ultrasound
- 9.4.2. 3D Ultrasound
- 9.4.3. Doppler Ultrasound
- 10. Disposable Fully Automatic Biopsy Device Market, by Application
- 10.1. Breast
- 10.1.1. Diagnostic
- 10.1.2. Screening
- 10.2. Liver
- 10.2.1. Diagnostic
- 10.2.2. Therapeutic
- 10.3. Lung
- 10.3.1. Diagnostic
- 10.3.2. Therapeutic
- 10.4. Prostate
- 10.4.1. Diagnostic
- 10.4.2. Therapeutic
- 11. Disposable Fully Automatic Biopsy Device Market, by End User
- 11.1. Ambulatory Surgical Centers
- 11.1.1. Freestanding Centers
- 11.1.2. Hospital Based Centers
- 11.2. Clinics
- 11.2.1. General Practice Clinics
- 11.2.2. Specialty Clinics
- 11.3. Diagnostic Laboratories
- 11.3.1. Hospital Based Laboratories
- 11.3.2. Independent Laboratories
- 11.4. Hospitals
- 11.4.1. Private Hospital
- 11.4.2. Public Hospital
- 12. Disposable Fully Automatic Biopsy Device Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. Disposable Fully Automatic Biopsy Device Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. Disposable Fully Automatic Biopsy Device Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. United States Disposable Fully Automatic Biopsy Device Market
- 16. China Disposable Fully Automatic Biopsy Device Market
- 17. Competitive Landscape
- 17.1. Market Concentration Analysis, 2025
- 17.1.1. Concentration Ratio (CR)
- 17.1.2. Herfindahl Hirschman Index (HHI)
- 17.2. Recent Developments & Impact Analysis, 2025
- 17.3. Product Portfolio Analysis, 2025
- 17.4. Benchmarking Analysis, 2025
- 17.5. AngioDynamics, Inc.
- 17.6. Argon Medical Devices, Inc.
- 17.7. B. Braun SE
- 17.8. Becton, Dickinson and Company
- 17.9. Boston Scientific Corporation
- 17.10. Cardinal Health, Inc.
- 17.11. Cook Medical LLC
- 17.12. Devicor Medical Products, Inc.
- 17.13. FUJIFILM Corporation
- 17.14. Hologic, Inc.
- 17.15. Johnson & Johnson
- 17.16. Medtronic plc
- 17.17. Merit Medical Systems, Inc.
- 17.18. Olympus Corporation
- 17.19. Siemens Healthineers AG
- 17.20. Stryker Corporation
- 17.21. Teleflex Incorporated
- 17.22. Terumo Corporation
- 17.23. Thermo Fisher Scientific Inc.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
